Maryland Venture Fund Provides $1,000,000 Investment to Cellphire

Governor Martin O’Malley and The Maryland Department of Business and Economic Development announced today that Cellphire has received a $1 million investment through the State’s InvestMaryland program. “Supporting entrepreneurs and innovators like those at Cellphire is a central piece of Maryland’s broad support of the startups and small businesses that move our Innovation Economy forward and keep our State competitive in the 21st Century,” said Governor O’Malley. “Maryland is a center of healing and discovery. The technology being developed by Cellphire has the potential to improve care and save lives around the globe.”

For the full article click: http://www.choosemaryland.org/pressroom/pages/cellphire.aspx

# # #

 About Cellphire, Inc. 

Cellphire, Inc. (www.cellphire.com) is working to solve the ubiquitous shortage of platelets for treatment of traumatic bleeding and other blood-related problems.  Platelets are critical to the body’s vascular system, responsible for the body’s ability to stop bleeding.  Unlike other blood products that can be frozen and stockpiled for use when needed, platelets must be stored at room temperature, and they spoil after just five days. Cellphire’s lead product, Thrombosomes®, a human platelet-derived hemostatic agent, uses a proprietary technology to freeze-dry platelets into a powder that can be stored for years, then reconstituted and brought back to life with sterilized water. Cellphire’s platform technology has tremendous potential across a wide range of medical applications from trauma to wound care, anti-coagulant reversal, imaging, targeted drug delivery and regenerative medicine.  

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipated”, “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Cellphire’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, increased regulatory requirements, Cellphire’s reliance on third parties over which it may not always have full control, and others. Any forward-looking statements speak only as of the date of this press release and are based on information available to Cellphire as of the date of this release, and Cellphire assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Thomas Dann
(240) 268-2489
tdann@cellphire.com

 

Source:  Cellphire, Inc.